UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 58

Sortiert nach

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Annals of oncology, 2019-03, Vol.30 (3), p.397-404

2019

Volltextzugriff (PDF)

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Annals of oncology, 2019-03, Vol.30 (3), p.405-411

2019

Volltextzugriff (PDF)

Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer

JNCI : Journal of the National Cancer Institute, 2004-05, Vol.96 (10), p.759-769

2004

Volltextzugriff (PDF)

Accelerated, Hypofractionated Whole-Breast Radiation Therapy in Women With Breast Cancer: A Phase 2 Trial

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.S269-S270

2014

Volltextzugriff (PDF)

Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups

Annals of oncology, 2009-10, Vol.20 (10), p.1653-1659

2009

Volltextzugriff (PDF)

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

The New England journal of medicine, 2015-11, Vol.373 (21), p.2005-2014

2015

Volltextzugriff (PDF)

5BA Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry

European journal of cancer (1990), 2015-09, Vol.51, p.S714-S714

2015

Volltextzugriff (PDF)

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

The New England journal of medicine, 2018-07, Vol.379 (2), p.111-121

2018

Volltextzugriff (PDF)

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

The New England journal of medicine, 2019-02, Vol.380 (7), p.617-628

2019

Volltextzugriff (PDF)

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

The New England journal of medicine, 2018-07, Vol.379 (2), p.122-137

2018

Volltextzugriff (PDF)

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

The New England journal of medicine, 2015-07, Vol.373 (3), p.209-219

2015

Volltextzugriff (PDF)

Clinical Toxicity in Hypofractionated and Conventionally Fractionated Radiation in Breast Cancer Patients with Germline ATM Mutations

International journal of radiation oncology, biology, physics, 2022-11, Vol.114 (3), p.e31

2022

Volltextzugriff (PDF)

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

The New England journal of medicine, 2015-01, Vol.372 (5), p.436-446

2015

Volltextzugriff (PDF)

First Results of the Primary Outcome of a Phase II Prospective Clinical Trial to Assess the Feasibility of Preoperative Radiation Boost in Breast Cancer Patients

International journal of radiation oncology, biology, physics, 2023-10, Vol.117 (2), p.S137-S137

2023

Volltextzugriff (PDF)

APBI (Accelerated Partial-Breast Irradiation) Versus WBI (Whole-Breast Irradiation) Delivered with the Same Dose Fractionation: A Propensity Score Matched Analysis of Two Prospective Studied Cohorts

International journal of radiation oncology, biology, physics, 2019-09, Vol.105 (1), p.E14-E14

2019

Volltextzugriff (PDF)

Utilization of Hypofractionated Whole-Breast Radiotherapy with Concurrent Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy

International journal of radiation oncology, biology, physics, 2019-09, Vol.105 (1), p.E31-E32

2019

Volltextzugriff (PDF)

Reconstruction Outcomes in a Multi-Institution Prospective Phase II Hypofractionated Post-Mastectomy Radiation Therapy Trial

International journal of radiation oncology, biology, physics, 2020-11, Vol.108 (3), p.S11-S11

2020

Volltextzugriff (PDF)

204TiP A phase II study of HER3-DXD in patients (pts) with metastatic breast cancer (MBC)

Annals of oncology, 2022-05, Vol.33, p.S220-S220

2022

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of LU79553, a DNA Intercalating Bisnaphthalimide, in Patients With Solid Malignancies

Journal of clinical oncology, 2001-02, Vol.19 (3), p.857-869

2001

Volltextzugriff (PDF)

Abstract OT1-05-01: A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor, in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.OT1-05-01-OT1-05-01

2018

Volltextzugriff (PDF)

Abstract OT3-05-10: A single arm phase II study of palbociclib in combination with tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.OT3-05-10-OT3-05-10

2018

Volltextzugriff (PDF)

Five-Year Results of a Prospective Phase 2 Trial Evaluating Three-Week Hypofractionated Whole Breast Radiation Therapy with Boost

International journal of radiation oncology, biology, physics, 2018-11, Vol.102 (3), p.S79-S79

2018

Volltextzugriff (PDF)

Phase I Clinical and Pharmacologic Study of 13-cis-Retinoic Acid, Interferon Alfa, and Paclitaxel in Patients With Prostate Cancer and Other Advanced Malignancies

Journal of clinical oncology, 1999-07, Vol.17 (7), p.2213-2218

1999

Volltextzugriff (PDF)

Abstract P2-01-01: Trajectory patterns of circulating tumor cells (CTC) in chemotherapy-treated metastatic breast cancer (MBC) patients predict poor clinical outcomes: CALGB 40502 (Alliance)/NCCTG N063H study

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P2-P2-01-01

2018

Volltextzugriff (PDF)

A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin

Clinical cancer research, 1995-03, Vol.1 (3), p.269-276

1995

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(55)

Publikationsform

Artikel
(58)

Sprache

Englisch
(58)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Humans
(28)
Female
(27)
Middle Aged
(26)
Science & Technology
(26)
Adult
(25)
Life Sciences & Biomedicine
(25)
Aged
(21)
Oncology
(19)
Chemotherapy
(15)
Antineoplastic Agents
(11)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
Biological And Medical Sciences
(11)
Breast Cancer
(11)
Breast Neoplasms - Drug Therapy
(11)
Male
(11)
Medical Sciences
(11)
Pharmacology. Drug Treatments
(11)
Disease-Free Survival
(9)
Aged, 80 And Over
(8)
Breast Neoplasms - Genetics
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer

Accelerated, Hypofractionated Whole-Breast Radiation Therapy in Women With Breast Cancer: A Phase 2 Trial

Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

5BA Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Clinical Toxicity in Hypofractionated and Conventionally Fractionated Radiation in Breast Cancer Patients with Germline ATM Mutations

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

First Results of the Primary Outcome of a Phase II Prospective Clinical Trial to Assess the Feasibility of Preoperative Radiation Boost in Breast Cancer Patients

APBI (Accelerated Partial-Breast Irradiation) Versus WBI (Whole-Breast Irradiation) Delivered with the Same Dose Fractionation: A Propensity Score Matched Analysis of Two Prospective Studied Cohorts

Utilization of Hypofractionated Whole-Breast Radiotherapy with Concurrent Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy

Reconstruction Outcomes in a Multi-Institution Prospective Phase II Hypofractionated Post-Mastectomy Radiation Therapy Trial

204TiP A phase II study of HER3-DXD in patients (pts) with metastatic breast cancer (MBC)

Phase I and Pharmacokinetic Study of LU79553, a DNA Intercalating Bisnaphthalimide, in Patients With Solid Malignancies

Abstract OT1-05-01: A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor, in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer

Abstract OT3-05-10: A single arm phase II study of palbociclib in combination with tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer

Five-Year Results of a Prospective Phase 2 Trial Evaluating Three-Week Hypofractionated Whole Breast Radiation Therapy with Boost

Phase I Clinical and Pharmacologic Study of 13-cis-Retinoic Acid, Interferon Alfa, and Paclitaxel in Patients With Prostate Cancer and Other Advanced Malignancies

Abstract P2-01-01: Trajectory patterns of circulating tumor cells (CTC) in chemotherapy-treated metastatic breast cancer (MBC) patients predict poor clinical outcomes: CALGB 40502 (Alliance)/NCCTG N063H study

A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin

Suchergebnisse filtern